BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
8.96
+0.20 (2.28%)
At close: Jul 14, 2025, 4:00 PM
8.94
-0.02 (-0.23%)
After-hours: Jul 14, 2025, 4:16 PM EDT
BioCryst Pharmaceuticals Employees
BioCryst Pharmaceuticals had 580 employees as of December 31, 2024. The number of employees increased by 44 or 8.21% compared to the previous year.
Employees
580
Change (1Y)
44
Growth (1Y)
8.21%
Revenue / Employee
$868,078
Profits / Employee
-$92,190
Market Cap
1.88B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
BCRX News
- 5 days ago - BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National Summit - GlobeNewsWire
- 7 days ago - BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development - GlobeNewsWire
- 11 days ago - BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 17 days ago - BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million - GlobeNewsWire
- 4 weeks ago - BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI - GlobeNewsWire
- 4 weeks ago - ORLADEYO® (berotralstat) Approved in Colombia - GlobeNewsWire
- 5 weeks ago - BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries - GlobeNewsWire
- 6 weeks ago - BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology - GlobeNewsWire